Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Short Interest Down 28.6% in February

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 40,600 shares, a decline of 28.6% from the January 31st total of 56,900 shares. Based on an average daily volume of 1,061,000 shares, the short-interest ratio is presently 0.0 days.

Ono Pharmaceutical Trading Up 0.6 %

Shares of OTCMKTS:OPHLY traded up $0.02 on Tuesday, hitting $3.58. 305,020 shares of the company’s stock were exchanged, compared to its average volume of 519,690. Ono Pharmaceutical has a 1-year low of $3.21 and a 1-year high of $5.67. The firm’s 50-day moving average is $3.41 and its 200 day moving average is $3.95.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.